Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A study to find out more about biomarkers in Hodgkin lymphoma (BACH)
This study is looking at biomarkers in tissue and blood samples of people with Hodgkin lymphoma to help tell how well the treatment is working.
This study is for people living in Scotland.
More about this trial
In this study, doctors will use
- blood samples taken before, during and after treatment
- cancer samples (
biopsies) taken when you were diagnosed
They use these to look for the CCL17 biomarker. Researchers think this biomarker can help tell how well the treatment is working.
The aims of this study are to
- develop a rapid biomarker test for CCL17
- find out if the CCL17 can be used to show how a treatment is working
Who can enter
The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
You may be able to join this study if you live in Scotland and all of the following apply. You
- Have a recent diagnosis of Hodgkin lymphoma
- Are at least 16 years old
The researchers need about 80 people across Scotland to take part.
First, the study team asks you some questions about
- your age
- your ethnic background
- your allergies
- if you have had an infection with mononucleosis (also called glandular fever or mono)
You have blood tests before the start of your treatment and then
- twice during treatment (before your 2nd and 3rd chemotherapy treatment cycle)
- at the end of treatment
- during your
The blood tests will be done at the same time you have other blood tests that are part of your normal care.
The study team may ask to use a sample of your cancer taken when you were diagnosed to check the CCL17 biomarker.
They may also look for a virus called Epstein Barr virus (EBV) that is associated with some cases of Hodgkin lymphoma.
As part of your normal care, the doctors might ask you to have a PET-CT scan before and then after 2 treatment cycles of chemotherapy. This is to check how the treatment is working.
If this happens, the study team will look at the images together with the results of the blood tests.
The study team will look at your medical records to find out about you and your
Only people involved in this research will look at your records and your details will be kept confidential.
You do not have any extra visits as part of this study. Your blood tests will be done at the same time as you have other tests that are part of your normal care.
There are no side effects associated with taking part in this study.
How to join a clinical trial
Professor Ruth Jarrett
Scottish Government Health Directorates Chief Scientist Office (CSO)
NHS Greater Glasgow and Clyde